Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. AustraliŽ
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. Nieuws
  7. Persberichten
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
OverzichtGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningen 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť CLINUVEL PHARMACEUTICALS LIMITED
14/09CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Confer..
PU
27/08CLINUVEL PHARMACEUTICALS : Investor Webinar Financial Results
PU
26/08CLINUVEL PHARMACEUTICALS : Newsletter 4 - August 2021
PU
26/08CLINUVEL PHARMACEUTICALS : Corporate Presentation - FY2021 Results
PU
26/08CLINUVEL PHARMACEUTICALS : Delivers Record Revenues and Profit
PU
26/08CLINUVEL PHARMACEUTICALS : Appendix 4E and Preliminary Financial Report
PU
10/08CLINUVEL PHARMACEUTICALS : Afamelanotide well tolerated by first stroke patients
PU
07/06CLINUVEL PHARMACEUTICALS : Media release - First stroke patient with afamelanoti..
PU
07/06CLINUVEL PHARMACEUTICALS : First stroke patient treated with afamelanotide
PU
04/06CLINUVEL PHARMACEUTICALS : Presentation to Jefferies Healthcare Conference
PU
03/06CLINUVEL PHARMACEUTICALS : Newsletter 3 - June 2021
PU
29/04CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
12/04CLINUVEL PHARMACEUTICALS : Strategic Update II - April 2021
PU
01/04CLINUVEL PHARMACEUTICALS : Newsletter II - April 2021
PU
24/03CLINUVEL PHARMACEUTICALS : Media Release - CLINUVEL expands DNA Repair Program
PU
24/03CLINUVEL PHARMACEUTICALS : SCENESSE to be assessed in xeroderma pigmentosum vari..
PU
24/03CLINUVEL expands DNA Repair Program
GL
10/03CLINUVEL PHARMACEUTICALS : Presentation - Daiwa Investment Conference Tokyo 2021
PU
25/02CLINUVEL PHARMACEUTICALS : Operations Update Webinar Released
PU
24/02CLINUVEL PHARMACEUTICALS : Reports Tenth Consecutive Half Year Profit
PU
24/02CLINUVEL PHARMACEUTICALS : Appendix 4D Half Yearly Report
PU
10/02CLINUVEL PHARMACEUTICALS : SCENESSE Granted Market Access in Israel
PU
27/01CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
24/01CLINUVEL PHARMACEUTICALS : Newsletter
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 3G
PU
2020CLINUVEL PHARMACEUTICALS : Newsletter
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSE DNA Repair Study Approved to Commence
PU
2020CLINUVEL PHARMACEUTICALS : Presentation Jefferies Virtual London Healthcare Conf..
PU
2020CLINUVEL PHARMACEUTICALS : Chair Letter
PU
2020CLINUVEL PHARMACEUTICALS : Results of Meeting
PU
2020CLINUVEL PHARMACEUTICALS : Chair Address
PU
2020CLINUVEL PHARMACEUTICALS : Managing Directors AGM Presentation
PU
2020CLINUVEL PHARMACEUTICALS : Strategic Update - Executive Summary
PU
2020CLINUVEL PHARMACEUTICALS : Strategic Update - Extended
PU
2020CLINUVEL PHARMACEUTICALS : Strategic Update – Executive Summary
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
2020CLINUVEL PHARMACEUTICALS : to Trial Innovative Drug in Stroke
AQ
2020CLINUVEL to Trial Innovative Drug in Stroke
GL
2020CLINUVEL PHARMACEUTICALS : Media Release - CLINUVEL to Trial Innovative Drug in ..
PU
2020CLINUVEL PHARMACEUTICALS : afamelanotide for Acute Stroke Patients
PU
2020CLINUVEL PHARMACEUTICALS : Media Release - TGA approves SCENESSE
PU
2020CLINUVEL PHARMACEUTICALS : Australian TGA approves SCENESSE
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSE DNA Repair Update
PU
2020CLINUVEL PHARMACEUTICALS : Further Research Coverage Initiated on CLINUVEL
PU
2020CLINUVEL PHARMACEUTICALS : Presentation - Value in the Vines Investor Conference
PU
2020CLINUVEL PHARMACEUTICALS : Annual General Meeting 2020
PU
2020CLINUVEL PHARMACEUTICALS : Annual Report to shareholders
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4G and Corporate Governance Statement
PU
2020CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
2020First patient dosed in SCENESSEģ DNA Repair Program
GL
2020CLINUVEL PHARMACEUTICALS : First patient dosed in SCENESSEģ DNA Repair Program
AQ
2020CLINUVEL PHARMACEUTICALS : Media Release - First patient dosed in SCENESSE DNA R..
PU
2020CLINUVEL PHARMACEUTICALS : First patient dosed in SCENESSE DNA Repair Program
PU
2020CLINUVEL progresses innovative DNA Repair Program
GL
2020CLINUVEL PHARMACEUTICALS : progresses innovative DNA Repair Program
AQ
2020CLINUVEL PHARMACEUTICALS : progresses innovative DNA Repair Program
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSE in DNA Repair
PU
2020CLINUVEL Opens VALLAURIX R&D Centre In Singapore
GL
2020CLINUVEL PHARMACEUTICALS : Corporate Presentation - 2020 Full Year Results
PU
2020CLINUVEL PHARMACEUTICALS : Declares Full Year Dividend
PU
2020CLINUVEL PHARMACEUTICALS : Full Year Results
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4E and Preliminary Financial Report
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4C – quarterly
PU
2020CLINUVEL PHARMACEUTICALS : Corporate Update
PU
2020CLINUVEL PHARMACEUTICALS : PRÉNUMBRAģ - CLINUVEL's Second Afamelanotide Formulat..
AQ
2020CLINUVEL PHARMACEUTICALS : Lapse and Forfeit of Unlisted Conditional Performance..
PU
2020MEDIA RELEASE : SCENESSEģ to be prescribed in China
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSEģ to be Prescribed in China
AQ
2020CLINUVEL PHARMACEUTICALS : First US Patients to be treated with SCENESSEģ
PU
2020CLINUVEL PHARMACEUTICALS : Innovative drug launched for rare, isolating, “..
AQ
2020CLINUVEL PHARMACEUTICALS : to Launch SCENESSEģ in USA in April
PU
2020CLINUVEL PHARMACEUTICALS : to Launch SCENESSE in USA in April
PU
2020CLINUVEL PHARMACEUTICALS : US Distribution Update
PU
2020CLINUVEL PHARMACEUTICALS : Chair Letter to Shareholders
PU
2020CLINUVEL PHARMACEUTICALS : Corporate Presentation Half Year Results
PU
1  2  3  4Volgende
Volgende evenement op CLINUVEL PHARMACEUTICALS LIMITED
29/10/21